ArticleFrontiers in medicine2024
Protective effects of docosahexaenoic acid combined with bilberry extract on myopic Guinea pigs.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the protective effects of docosahexaenoic acid (DHA) combined with bilberry extract (BE) on myopic guinea pigs. In total, 105 healthy pigmented guinea pigs aged 2 weeks were selected and randomly divided into five groups. The normal control (NC) group received no treatment, while the experimental groups wore -6.0D lenses on the right eye to establish an animal model of lens-induced myopia (LIM). These groups were further divided based on different treatments: normal feeding, DHA treatment, BE treatment, and combined DHA + BE treatment. Refractive error and axial length for both eyes were measured before modeling, after 4 weeks of modeling, and after 8 weeks of treatment. Fundus examination was performed, and choroidal thickness, choroidal vascularity index (CVI), maximal mixed response in dark adaptation (Max-ERG), and cone cell response in light adaptation (Cone-ERG) were measured. After 8 weeks of treatment, we observed a significant reduction in refractive error and shortening of axial length, improvement in fundus condition, and increased choroidal thickness and CVI in the LIM + DHA + BE group. Electroretinogram (ERG) showed that the amplitudes of a-wave and b-wave were enhanced in both Max-ERG and Cone-ERG tests. The LIM + DHA + BE group exhibited superior effects compared to the LIM + DHA group and the LIM + BE group. The combination of DHA and BE delayed the progression of LIM in guinea pigs and was more effective than DHA or BE alone. The synergistic effect of DHA and BE offers a new approach to the prevention and treatment of myopia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.